POstmastectomy radioThErapy in Node-posiTive breast cancer with or without Internal mAmmary nodaL irradiation (POTENTIAL): a study protocol for a multicenter prospective phase III randomized controlled trial

Xu-Ran Zhao, Hui Fang, Yu Tang, Zhi-Hui Hu, Hao Jing, Lin Liang, Xue-Na Yan, Yong-Wen Song, Jing Jin, Yue-Ping Liu, Bo Chen, Yuan Tang, Shu-Nan Qi, Ning Li, Ning-Ning Lu, Kuo Men, Chen Hu, Yu-Hui Zhang, Ye-Xiong Li, Shu-Lian Wang, Xu-Ran Zhao, Hui Fang, Yu Tang, Zhi-Hui Hu, Hao Jing, Lin Liang, Xue-Na Yan, Yong-Wen Song, Jing Jin, Yue-Ping Liu, Bo Chen, Yuan Tang, Shu-Nan Qi, Ning Li, Ning-Ning Lu, Kuo Men, Chen Hu, Yu-Hui Zhang, Ye-Xiong Li, Shu-Lian Wang

Abstract

Background: Various randomized trials have demonstrated that postmastectomy radiotherapy (RT) to the chest wall and comprehensive regional nodal areas improves survival in patients with axillary node-positive breast cancer. Controversy exists as to whether the internal mammary node (IMN) region is an essential component of regional nodal irradiation. Available data on the survival benefit of IMN irradiation (IMNI) are conflicting. The patient populations enrolled in previous studies were heterogeneous and most studies were conducted before modern systemic treatment and three-dimensional (3D) radiotherapy (RT) techniques were introduced. This study aims to assess the efficacy and safety of IMNI in the context of modern systemic treatment and computed tomography (CT)-based RT planning techniques.

Methods: POTENTIAL is a prospective, multicenter, open-label, parallel, phase III, randomized controlled trial investigating whether IMNI improves disease-free survival (DFS) in high-risk breast cancer with positive axillary nodes (pN+) after mastectomy. A total of 1800 patients will be randomly assigned in a 1:1 ratio to receive IMNI or not. All patients are required to receive ≥ six cycles of anthracycline and/or taxane-based chemotherapy. Randomization will be stratified by institution, tumor location (medial/central vs. other quadrants), the number of positive axillary nodes (1-3 vs. 4-9 vs. ≥10), and neoadjuvant chemotherapy (yes vs. no). Treatment will be delivered with CT-based 3D RT techniques, including 3D conformal RT, intensity-modulated RT, or volumetric modulated arc therapy. The prescribed dose is 50 Gy in 25 fractions or 43.5 Gy in 15 fractions. Tiered RT quality assurance is required. After RT, patients will be followed up at regular intervals. Oncological and toxilogical outcomes, especially cardiac toxicities, will be assessed.

Discussion: This trial design is intended to overcome the limitations of previous prospective studies by recruiting patients with pN+ breast cancer, using DFS as the primary endpoint, and prospectively assessing cardiac toxicities and requiring RT quality assurance. The results of this study will provide high-level evidence for elective IMNI in patients with breast cancer after mastectomy.

Trial registration: ClinicalTrails.gov , NCT04320979 . Registered 25 Match 2020, https://ichgcp.net/clinical-trials-registry/NCT04320979.

Keywords: Breast cancer; Internal mammary node irradiation; Postmastectomy radiotherapy; Survival outcome; Toxicity.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Flow chart of the POTENTIAL trial

References

    1. Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, Kjaer M, Gadeberg CC, Mouridsen HT, Jensen MB, Zedeler K. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish breast Cancer cooperative group 82b trial. N Engl J Med. 1997;337(14):949–955. doi: 10.1056/NEJM199710023371401.
    1. Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, Kamby C, Kjaer M, Gadeberg CC, Rasmussen BB, Blichert-Toft M, Mouridsen HT. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish breast Cancer cooperative group DBCG 82c randomised trial. Lancet. 1999;353(9165):1641–1648. doi: 10.1016/S0140-6736(98)09201-0.
    1. Ragaz J, Jackson SM, Le N, Plenderleith IH, Spinelli JJ, Basco VE, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med. 1997;337(14):956–962. doi: 10.1056/NEJM199710023371402.
    1. McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383(9935):2127–2135. doi: 10.1016/S0140-6736(14)60488-8.
    1. Huang O, Wang L, Shen K, Lin H, Hu Z, Liu G, Wu J, Lu J, Shao Z, Han Q, Shen Z. Breast cancer subpopulation with high risk of internal mammary lymph nodes metastasis: analysis of 2,269 Chinese breast cancer patients treated with extended radical mastectomy. Breast Cancer Res Treat. 2008;107(3):379–387. doi: 10.1007/s10549-007-9561-4.
    1. Chen RC, Lin NU, Golshan M, Harris JR, Bellon JR. Internal mammary nodes in breast cancer: diagnosis and implications for patient management -- a systematic review. J Clin Oncol. 2008;26(30):4981–4989. doi: 10.1200/JCO.2008.17.4862.
    1. Chen L, Gu Y, Leaw S, Wang Z, Wang P, Hu X, Chen J, Lu J, Shao Z. Internal mammary lymph node recurrence: rare but characteristic metastasis site in breast cancer. BMC Cancer. 2010;10(1):479. doi: 10.1186/1471-2407-10-479.
    1. Lacour J, Bucalossi P, Cacers E, Jacobelli G, Koszarowski T, Le M, et al. Radical mastectomy versus radical mastectomy plus internal mammary dissection. Five-year results of an international cooperative study. Cancer. 1976;37(1):206–214. doi: 10.1002/1097-0142(197601)37:1<206::AID-CNCR2820370130>;2-M.
    1. Veronesi U, Marubini E, Mariani L, Valagussa P, Zucali R. The dissection of internal mammary nodes does not improve the survival of breast cancer patients. 30-year results of a randomised trial. Eur J Cancer. 1999;35(9):1320–1325. doi: 10.1016/S0959-8049(99)00133-1.
    1. Hennequin C, Bossard N, Servagi-Vernat S, Maingon P, Dubois JB, Datchary J, Carrie C, Roullet B, Suchaud JP, Teissier E, Lucardi A, Gerard JP, Belot A, Iwaz J, Ecochard R, Romestaing P. Ten-year survival results of a randomized trial of irradiation of internal mammary nodes after mastectomy. Int J Radiat Oncol Biol Phys. 2013;86(5):860–866. doi: 10.1016/j.ijrobp.2013.03.021.
    1. Thorsen LB, Offersen BV, Danø H, Berg M, Jensen I, Pedersen AN, et al. DBCG-IMN: a population-based cohort study on the effect of internal mammary node irradiation in early node-positive breast Cancer. J Clin Oncol. 2016;34(4):314–320. doi: 10.1200/JCO.2015.63.6456.
    1. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, Correa C, Cutter D, Gagliardi G, Gigante B, Jensen MB, Nisbet A, Peto R, Rahimi K, Taylor C, Hall P. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987–998. doi: 10.1056/NEJMoa1209825.
    1. Dess RT, Liss AL, Griffith KA, Marsh RB, Moran JM, Mayo C, Koelling TM, Jagsi R, Hayman JA, Pierce LJ. Ischemic cardiac events following treatment of the internal mammary nodal region using contemporary radiation planning techniques. Int J Radiat Oncol Biol Phys. 2017;99(5):1146–1153. doi: 10.1016/j.ijrobp.2017.06.2459.
    1. van den Bogaard VA, Ta BD, van der Schaaf A, Bouma AB, Middag AM, Bantema-Joppe EJ, et al. Validation and modification of a prediction model for acute cardiac events in patients with breast Cancer treated with radiotherapy based on three-dimensional dose distributions to cardiac substructures. J Clin Oncol. 2017;35(11):1171–1178. doi: 10.1200/JCO.2016.69.8480.
    1. Mohamad O, Shiao J, Zhao B, Roach K, Ramirez E, Vo DT, Thomas K, Gu X, Spangler A, Albuquerque K, Rahimi A. Deep inspiration breathhold for left-sided breast cancer patients with unfavorable cardiac anatomy requiring internal mammary nodal irradiation. Pract Radiat Oncol. 2017;7(6):e361–ee67. doi: 10.1016/j.prro.2017.04.006.
    1. Duane FK, McGale P, Teoh S, Mortimer C, Broggio J, Darby SC, Dodwell D, Lavery B, Oliveros S, Vallis KA, Taylor CW. International variation in criteria for internal mammary chain radiotherapy. Clin Oncol (R Coll Radiol) 2019;31(7):453–461. doi: 10.1016/j.clon.2019.04.007.
    1. Wang SL, Fang H, Song YW, Wang WH, Hu C, Liu YP, Jin J, Liu XF, Yu ZH, Ren H, Li N, Lu NN, Tang Y, Tang Y, Qi SN, Sun GY, Peng R, Li S, Chen B, Yang Y, Li YX. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2019;20(3):352–360. doi: 10.1016/S1470-2045(18)30813-1.
    1. Freidlin B, Korn EL, Gray R. A general inefficacy interim monitoring rule for randomized clinical trials. Clin Trials. 2010;7(3):197–208. doi: 10.1177/1740774510369019.
    1. Bekelman JE, Deye JA, Vikram B, Bentzen SM, Bruner D, Curran WJ, Jr, Dignam J, Efstathiou JA, FitzGerald TJ, Hurkmans C, Ibbott GS, Lee JJ, Merchant TE, Michalski J, Palta JR, Simon R, ten Haken RK, Timmerman R, Tunis S, Coleman CN, Purdy J. Redesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials--report of the National Cancer Institute work group on radiotherapy quality assurance. Int J Radiat Oncol Biol Phys. 2012;83(3):782–790. doi: 10.1016/j.ijrobp.2011.12.080.
    1. Kim KH, Noh JM, Kim YB, Chang JS, Keum KC, Huh SJ, Choi DH, Park W, Suh CO. Does internal mammary node irradiation affect treatment outcome in clinical stage II-III breast cancer patients receiving neoadjuv ant chemotherapy? Breast Cancer Res Treat. 2015;152(3):589–599. doi: 10.1007/s10549-015-3505-1.
    1. Stemmer SM, Rizel S, Hardan I, Adamo A, Neumann A, Goffman J, Brenner HJ, Pfeffer MR. The role of irradiation of the internal mammary lymph nodes in high-risk stage II to IIIA breast cancer patients after high-dose chemotherapy: a prospective sequential nonrandomized study. J Clin Oncol. 2003;21(14):2713–2718. doi: 10.1200/JCO.2003.09.096.
    1. Wang X, Luo J, Jin K, Chen X, Zhang L, Meng J, Zhang X, Zhang Z, Shao Z, Bazan JG, Guo X, Yang Z, Yu X. Internal mammary node irradiation improves 8-year survival in breast cancer patients: results from a retrospective cohort study in real-world setting. Breast Cancer. 2020;27(2):252–260. doi: 10.1007/s12282-019-01015-9.
    1. Chang JS, Park W, Kim YB, Lee IJ, Keum KC, Lee CG, Choi DH, Suh CO, Huh SJ. Long-term survival outcomes following internal mammary node irradiation in stage II-III breast cancer: results of a large retrospective study with 12-year follow-up. Int J Radiat Oncol Biol Phys. 2013;86(5):867–872. doi: 10.1016/j.ijrobp.2013.02.037.
    1. Luo J, Jin K, Chen X, Wang X, Yang Z, Zhang L, Mei X, Ma J, Zhang X, Zhou Z, Wang X, Jiang Y, Shao Z, Zhang Z, Guo X, Yu X. Internal mammary node irradiation (IMNI) improves survival outcome for patients with clinical stage II-III breast Cancer after preoperative systemic therapy. Int J Radiat Oncol Biol Phys. 2019;103(4):895–904. doi: 10.1016/j.ijrobp.2018.11.003.
    1. Cho WK, Chang JS, Park SG, Kim N, Choi DH, Kim H, Kim YB, Park W, Suh CO. Internal mammary node irradiation in node-positive breast cancer treated with mastectomy and taxane-based chemotherapy. Breast. 2021;59:37–43. doi: 10.1016/j.breast.2021.05.012.
    1. Olson RA, Woods R, Speers C, Lau J, Lo A, Truong PT, Tyldesley S, Olivotto IA, Weir L. Does the intent to irradiate the internal mammary nodes impact survival in women with breast cancer? A population-based analysis in British Columbia. Int J Radiat Oncol Biol Phys. 2012;83(1):e35–e41. doi: 10.1016/j.ijrobp.2011.11.066.
    1. Fowble B, Hanlon A, Freedman G, Nicolaou N, Hoffman J, Sigurdson E, Boraas M, Torosian M, Goldstein L. Internal mammary node irradiation neither decreases distant metastases nor improves survival in stage I and II breast cancer. Int J Radiat Oncol Biol Phys. 2000;47(4):883–894. doi: 10.1016/S0360-3016(00)00526-5.
    1. Obedian E, Haffty BG. Internal mammary nodal irradiation in conservatively-managed breast cancer patients: is there a benefit? Int J Radiat Oncol Biol Phys. 1999;44(5):997–1003. doi: 10.1016/S0360-3016(99)00135-2.
    1. Wang S, Wen G, Tang Y, Yang Y, Jing H, Wang J, Zhang J, Zhao X, Sun G, Jin J, Song Y, Liu Y, Fang H, Zhang Y, Li Y. Effectiveness of the AJCC 8th edition staging system for selecting patients with T1-2N1 breast cancer for post-mastectomy radiotherapy: a joint analysis of 1986 patients from two institutions. BMC Cancer. 2020;20(1):792. doi: 10.1186/s12885-020-07267-5.
    1. Taylor C, Correa C, Duane FK, Aznar MC, Anderson SJ, Bergh J, Dodwell D, Ewertz M, Gray R, Jagsi R, Pierce L, Pritchard KI, Swain S, Wang Z, Wang Y, Whelan T, Peto R, McGale P, for the Early Breast Cancer Trialists’ Collaborative Group Estimating the risks of breast Cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials. J Clin Oncol. 2017;35(15):1641–1649. doi: 10.1200/JCO.2016.72.0722.
    1. Taylor CW, Wang Z, Macaulay E, Jagsi R, Duane F, Darby SC. Exposure of the heart in breast Cancer radiation therapy: a systematic review of heart doses published during 2003 to 2013. Int J Radiat Oncol Biol Phys. 2015;93(4):845–853. doi: 10.1016/j.ijrobp.2015.07.2292.
    1. Yeh ET, Chang HM. Oncocardiology-past, present, and future: a review. JAMA Cardiol. 2016;1(9):1066–1072. doi: 10.1001/jamacardio.2016.2132.
    1. Thorsen LB, Thomsen MS, Overgaard M, Overgaard J, Offersen BV. Quality assurance of conventional non-CT-based internal mammary lymph node irradiation in a prospective Danish breast Cancer cooperative group trial: the DBCG-IMN study. Acta Oncol. 2013;52(7):1526–1534. doi: 10.3109/0284186X.2013.813643.
    1. Chung Y, Kim JW, Shin KH, Kim SS, Ahn SJ, Park W, Lee HS, Kim DW, Lee KC, Suh HS, Kim JH, Shin HS, Kim YB, Suh CO. Dummy run of quality assurance program in a phase 3 randomized trial investigating the role of internal mammary lymph node irradiation in breast cancer patients: Korean radiation oncology group 08-06 study. Int J Radiat Oncol Biol Phys. 2015;91(2):419–426. doi: 10.1016/j.ijrobp.2014.10.022.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner